CF PharmTech (HKG:2652) said Chinese regulators had accepted its marketing authorization application for tiotropium bromide inhalation powder for review, according to a Tuesday filing with the Hong Kong bourse.
The product is designed to treat bronchospasm associated with chronic obstructive pulmonary disease and help keep reduce exacerbations associated with the condition.